To include your compound in the COVID-19 Resource Center, submit it here.

Selecta's gout combo lacks longer-term efficacy in Phase II trial

Selecta Biosciences Inc. (NASDAQ:SELB) reported updated data from an open-label, U.S. Phase II trial of lead candidate SEL-212 to treat chronic, severe gout. SEL-212 is a non-immunogenic therapy comprising pegsiticase (SEL-037), a pegylated uricase, co-administered with SVP-Rapamycin (SEL-110), a nanoparticle encapsulating the immunomodulator

Read the full 438 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE